Michelle Longmire co-founded Medable in 2015, but it wasn’t until the Covid-19 pandemic that the drug-development software platform came into its own. Medable’s technology helps pharma giants such as AstraZeneca administer remote clinical trials and navigate the complications of pandemic shutdowns, saving time, money, and lives. The company’s valuation leapt from around $100 million to $2 billion in just 18 months, and it has raised more than $300 million in venture capital this year. Now Medable must scramble to keep up with demand. –As told to Tom FosterBefore becoming an entrepreneur, I was a practicing dermatologist and postdoc researcher at Stanford, searching for identical twins …
